Phase I study of single-dose oxaliplatin in Japanese patients with malignant tumors

Japanese Journal of Clinical Oncology

Volumn 36, Issue 5, 2006, Pages 295-300

  Shirao, Kuniaki ^a   Matsumura, Yasuhiro ^a   Yamada, Yasuhide ^a   Muro, Kei ^a   Gotoh, Masahiro ^a   Boku, Narikazu ^b   Ohtsu, Atsushi ^b   Nagashima, Fumio ^b   Sano, Yasushi ^b   Mutoh, Manabu ^b   Tanigawara, Yusuke ^c  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^c KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Oxaliplatin; Pharmacokinetics; Phase I study; Safety

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; OXALIPLATIN; PLATINUM DERIVATIVE; POTASSIUM; SODIUM;

ADULT; ADVANCED CANCER; ALOPECIA; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BONE MARROW SUPPRESSION; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; COLORECTAL SURGERY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EXCRETION; DRUG INFUSION; DRUG SAFETY; DYSESTHESIA; FATIGUE; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; HYPOKALEMIA; HYPONATREMIA; JAPAN; KIDNEY DYSFUNCTION; LEUKOPENIA; LIVER DYSFUNCTION; MALE; MAXIMUM TOLERATED DOSE; MEDICAL DECISION MAKING; MOTOR DYSFUNCTION; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NEUTROPENIA; PARESTHESIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; RACE DIFFERENCE; SENSORY NEUROPATHY; SINGLE DRUG DOSE; THROMBOCYTOPENIA; TREATMENT OUTCOME; ULTRAFILTRATION;

ADULT; ANOREXIA; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PERIPHERAL NERVOUS SYSTEM DISEASES; PLATINUM;

EID: 33745700671     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyl016     Document Type: Article

References (21)

1. Kidani Y, Inagaki K, Saito R. Synthesis and anti-tumor activities of platinum (II) complexes of 1, 2-diaminocyclohexane isomers and their related derivatives. J Clin Hematol Oncol 1977;7:197-209.
2. Kidani Y, Inagaki K, Tsukagoshi S. Examination of antitumor activities of platinum complexes of 1,2-diaminocyclohexane isomers and their related complexes. Gann 1976;67:921-2 (in Japanese).
3. Mathé G, Kidani Y, Noji M, Marel R, Bourut C, Chenu E. Antitumor activity of l-OHP in mice. Cancer Lett 1985;27:135-43.
4. Tashiro T, Kawada Y, Sakurai Y, Kidani Y. Antitumor activity of a new platinum complex, oxalato (trans-l-1, 2-diaminocyclohexane) platinum (II): New experimental data. Biomed Pharmacother 1989;43:251-60.
5. Rixe O, Ortuzar W, Alvarez M, Parker R, Reed E, Paull K et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's anticancer drug screen panel. Biochem Pharmacol 1996;52:1855-65.
6. Fukuda M, Ohe Y, Kanazawa F, Oka M, Hara K, Saijo N. Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin. Anticancer Res 1995;15:393-8.
7. Riccardi A, Ferlini C, Meco D, Mastrangelo R, Scambia G, Riccardi R. Antitumour activity of oxaliplatin in neuroblastoma cell lines. Eur J Cancer 1999;35:86-90.
8. Dunn TA, Schmoll FU, Grünwald V, Bokemeyer C, Casper J. Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines. Invest New Drugs 1997;15:109-14.
9. Silvestro L, Anal H, Sommer F, Trincal G, Taplero H. Comparative effects of a new platinum analog (trans-1,2-diamine-cyclohexane oxalate-platinum; L'OHP) with CDDP on various cells: Correlation with intracellular accumulation [abstract]. Proceedings of the Abstracts of the Third International Conference of Anticancer Research 1990; 1376 (no. 115).
10. Graham MA, Lockwood GF, Greenslade D, Brienza S, Bayssas M, Gamelin E. Clinical pharmacokinetics of oxaliplatin: A critical review. Clin Cancer Res 2000;6:1205-18.
11. Extra JM, Marty M, Brienza S, Misset JL. Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol 1998;25(2 Suppl 5): 13-22.
12. Machover D, Diaz-Rubio E, de Gramont A, Schilf A, Gastiaburu JJ, Brienza S, et al. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996;7:95-8.
13. de Gramont A, Vignoud J, Tournigand C, Louvet C, André T, Varette C, et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 1997;33:214-9
14. André T, Bensmaine MA, Louvet C, François E, Lucas V, Desseigne F, et al. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 1999;17:3560-8
15. Maindrault-Goebel F, Louvet C, André T, Carola E, Lotz JP, Molitor JL, et al. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer 1999;35:1338-42.
16. Maindrault-Goebel F, de Gramont A, Louvet C, André T, Carola E, Mabro M, et al. High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX7). Eur J Cancer 2001;37:1000-5.
17. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22:23-30.
18. Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 2004;22:229-37.
19. Taguchi T, Tsukagoshi S, Furue H, Niitani H, Noda K. Phase I clinical study of oxaliplatin. Jpn J Cancer Chemother 1998:25:1899-907 (in Japanese).
20. Shimoyama M. The Japanese edition of the National Cancer Institute-Common Toxicity Criteria. Jpn J Cancer Chemother 1999;26:1084-144 (in Japanese).
21. World Health Organization. WHO handbook for reporting results of cancer treatment [offset publication no.40]. Geneva (Switzerland): World Health Organization; 1979.